WhatPeptide

BAM-15

A mitochondrial protonophore uncoupler with EC₅₀ 1.4 μM (~7× more potent than DNP at 10.1 μM). Developed through a multi-institutional collaboration: Webster Santos at Virginia Tech and Kyle Hoehn at the University of Virginia (later UNSW Sydney). Selectively accumulates in lipid-rich tissues (liver, adipose). In mice, reversed diet-induced obesity without hyperthermia or reduced food intake. Continuum Biosciences (co-founded by Santos and Hoehn, 2017) is developing it.

Animal studies only Unregulated Exercise Mimetic

Written by WhatPeptide Editorial Team · Last updated 2026-03-18

Half-life

~1.7 hours in mice (oral gavage at 10 mg/kg; Alexopoulos et al.); ~3 hours under food admixture dosing (Axelrod et al.)

Dosage range

Mouse studies: 10 mg/kg oral gavage (PK profiling); efficacy studies used various routes. No established human dosing.

Administration

Oral

Research level

Animal only

How BAM-15 works

Selectively uncouples mitochondrial oxidative phosphorylation by transporting protons across the inner mitochondrial membrane, bypassing ATP synthase. Preferentially active in lipid-rich tissues (liver, adipose). Increases metabolic rate and fat oxidation without the narrow therapeutic window of classical uncouplers like DNP — no hyperthermia or food intake changes observed in animal studies.

Also known as: BAM15, N5,N6-bis(2-Fluorophenyl)[1,2,5]oxadiazolo[3,4-b]pyrazine-5,6-diamine

Research relevance

Fat Loss
Moderate relevance 70

Side effects & safety

No obvious toxicity at tested doses in animals No hyperthermia (unlike DNP) No reduction in food intake No human safety data available

Contraindications

No human data — all contraindications theoretical
Pre-existing mitochondrial disorders
Pregnancy

Consult a healthcare provider before use if any of these apply to you.

FAQ

What is BAM-15? +
A mitochondrial protonophore uncoupler with EC₅₀ 1.4 μM (~7× more potent than DNP at 10.1 μM). Developed through a multi-institutional collaboration: Webster Santos at Virginia Tech and Kyle Hoehn at the University of Virginia (later UNSW Sydney). Selectively accumulates in lipid-rich tissues (liver, adipose). In mice, reversed diet-induced obesity without hyperthermia or reduced food intake. Continuum Biosciences (co-founded by Santos and Hoehn, 2017) is developing it. Its mechanism of action is based primarily on animal and in-vitro studies.
What is BAM-15 researched for? +
BAM-15 has the strongest research relevance for Fat Loss. Evidence is based primarily on animal and in-vitro studies.
What are the side effects of BAM-15? +
Reported side effects include No obvious toxicity at tested doses in animals, No hyperthermia (unlike DNP), No reduction in food intake, No human safety data available. Key contraindications: No human data — all contraindications theoretical; Pre-existing mitochondrial disorders; Pregnancy.
Is BAM-15 FDA approved? +
BAM-15 is not FDA-approved. It is available as a research compound or through compounding pharmacies in some jurisdictions.
How is BAM-15 administered? +
BAM-15 is typically administered via oral route. Researched dosage range: Mouse studies: 10 mg/kg oral gavage (PK profiling); efficacy studies used various routes. No established human dosing.. Half-life: ~1.7 hours in mice (oral gavage at 10 mg/kg; Alexopoulos et al.); ~3 hours under food admixture dosing (Axelrod et al.).

Explore similar peptides

SLU-PP-332

Animal studies only

Exercise Mimetic

A small-molecule pan-agonist of estrogen-related receptors (ERRα/β/γ) developed at Washington University/St. Louis College of Pharmacy by Thomas Burris. EC₅₀: ERRα ~98 nM, ERRβ ~230 nM, ERRγ ~430 nM (~2- to 4-fold selective for ERRα depending on subtype). CAS: 303760-60-3. Not orally bioavailable — administered IP in animal studies. Successor compound SLU-PP-915 was developed for oral delivery.

Orforglipron

Strong evidence

GLP-1 Agonist

A non-peptide oral GLP-1 receptor agonist discovered by Chugai Pharmaceutical and licensed to Eli Lilly in 2018. The first small-molecule GLP-1 agonist to reach Phase 3. ATTAIN-1 (NCT05869903, 3,127 adults, 72 weeks) showed 12.4% placebo-subtracted weight loss at 36 mg (efficacy estimand) or 11.2% vs 2.1% placebo (treatment-regimen estimand). NDA submitted to FDA December 2025.

Retatrutide

Preliminary evidence

GLP-1/GIP/Glucagon Agonist

An investigational triple agonist (GLP-1/GIP/glucagon) with large early-stage weight-loss signals in phase 2 studies.

Semaglutide

Strong evidence

GLP-1 Agonist

A long-acting GLP-1 receptor agonist with robust randomized evidence for glycemic control and body-weight reduction.